RecruitingPHASE1, PHASE2NCT03676504

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital Heidelberg
Principal Investigator
Prof. Dr. Michael Schmitt
University Hospital Heidelberg, Department V
Intervention
CD19.CAR T Cells(biological)
Enrollment
68 enrolled
Eligibility
3 years · All sexes
Timeline
20182027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03676504 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials